p.77 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES Circulation. 2024;149:e1313–e1410. DOI: 10.1161/CIR.0000000000001251 June 11, 2024 e1389 13 Ciccarone E, Di Castelnuovo A, Salcuni M, et al. A high-score Mediter- ranean dietary pattern is associated with a reduced risk of peripheral arterial disease in Italian patients with type 2 diabetes. J Thromb Haemost. 2003;1:1744–1752. 14. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779– 785. 15. Wan D, Li V, Banfield L, et al. Diet and Nutrition in Peripheral Artery Disease: A Systematic Review. Can J Cardiol. 2022;38:672–680. 16. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577. 17. Khandanpour N, Loke YK, Meyer FJ, et al. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2009;38:316–322. 18. Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev. 2013;CD003285. 19. Villarruz-Sulit MV, Forster R, Dans AL, et al. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2020;5:CD002785. 20. Ujueta F, Arenas IA, Escolar E, et al. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT). J Diabetes Complications. 2019;33:490–494. 21. Barbarawi M, Kheiri B, Zayed Y, et al. Vitamin D supplementation and cardiovascular disease risks in more than 83000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiol. 2019;4:765–776. 22. Veronese N, De Rui M, Bolzetta F, et al. Serum 25-hydroxyvitamin D and the incidence of peripheral artery disease in the elderly: the Pro.V.A study. J Atheroscler Thromb. 2015;22:726–734. 23. Rapson IR, Michos ED, Alonso A, et al. Serum 25-hydroxyvitamin D is associated with incident peripheral artery disease among white and black adults in the ARIC study cohort. Atherosclerosis. 2017;257:123–129. 24. Mazidi M, Wong ND, Katsiki N, et al. Dietary patterns, plasma vitamins and trans fatty acids are associated with peripheral artery disease. Lipids Health Dis. 2017;16:254. 25. Krishna SM. Vitamin D as a protector of arterial health: potential role in peripheral arterial disease formation. Int J Mol Sci. 2019;20:4907. 26. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40. 27. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004. 28. Smolderen KG, Lee M, Arora T, et al. Peripheral artery disease and CO- VID-19 outcomes: insights from the Yale DOM-CovX registry. Curr Probl Cardiol. 2021;101007. 29. Kuno T, Takahashi M, Obata R, et al. Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City. Am Heart J. 2020;226:24–25. 30. Centers for Disease Control and Prevention. Vaccines for COVID-19. Centers for Disease Control and Prevention. Accessed August 22, 2023. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html. 5.7. Medication for Leg Symptoms in Chronic Symptomatic PAD 1. Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014;CD003748. 2. Mohammed M, Gosch K, Safley D, et al. Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD. Int J Cardiol. 2020;316:222–228. 3. Ma B, Fan X, Liu P. Therapeutic effects of medication use on intermittent claudication: a network meta-analysis. J Cardiovasc Pharmacol. 2021;77:253–262. 4. Farkas K, Kolossvary E, Jarai Z. Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study. Vasa. 2020;49:235–242. 5. Soga Y, Hamasaki T, Edahiro R, et al. Sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: midterm followup from the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) study. J Endovasc Ther. 2018;25:306–312. 6. Megaly M, Abraham B, Saad M, et al. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med. 2019;24:313–323. 7. Zen K, Takahara M, Iida O, et al. Drug-eluting stenting for femoropopliteal le- sions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. J Vasc Surg. 2017;65:720– 725. 8. Otsuka Pharmaceutical Co. Pletal (cilostazol) [package insert]. Updat- ed May 17, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/020863s024lbl.pdf. 9. Packer M, Carver JR, Rodeheffer RJ, et al, The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475. 10. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008;47:330–336. 11. Salhiyyah K, Forster R, Senanayake E, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015;9:CD005262. 12. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523– 530. 13. Villarruz-Sulit MV, Forster R, Dans AL, et al. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2020;5:CD002785. 14. Lee C, Nelson PR. Effect of cilostazol prescribed in a pragmatic treat- ment program for intermittent claudication. Vasc Endovascular Surg. 2014;48:224–229. 5.8. Preventive Foot Care for PAD 1. Miikkola M, Lantta T, Suhonen R, et al. Challenges of foot self-care in older people: a qualitative focus-group study. J Foot Ankle Res. 2019;12:5. 2. Nguyen TPL, Edwards H, Do TND, et al. Effectiveness of a theory-based foot care education program (3STEPFUN) in improving foot self-care behaviours and foot risk factors for ulceration in people with type 2 diabetes. Diabetes Res Clin Pract. 2019;152:29–38. 3. Siersma V, Koster-Rasmussen R, Bruun C, et al. Visual impairment and mortality in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2019;7:e000638. 4. Polikandrioti M, Vasilopoulos G, Koutelekos I, et al. Quality of life in diabetic foot ulcer: associated factors and the impact of anxiety/depression and adherence to self-care. Int J Low Extrem Wounds. 2020;19:165–179. 5. Chen H, Cai C, Xie J. The effect of an intensive patients' education program on anxiety, depression and patient global assessment in diabetic foot ulcer patients with Wagner grade 1/2: a randomized, controlled study. Medicine (Baltimore). 2020;99:e18480. 6. Jupiter DC, Thorud JC, Buckley CJ, et al. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review. Int Wound J. 2016;13:892–903. 7. Hoogeveen RC, Dorresteijn JA, Kriegsman DM, et al. Complex interventions for preventing diabetic foot ulceration. Cochrane Database Syst Rev. 2015;CD007610. 8. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(Suppl 2):3S-21S. 9. Bus SA. Innovations in plantar pressure and foot temperature measurements in diabetes. Diabetes Metab Res Rev. 2016;32(Suppl 1):221–226. 10. Kolte D, Parikh SA, Piazza G, et al. Vascular teams in peripheral vascular disease. J Am Coll Cardiol. 2019;73:2477–2486. 11. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. J Vasc Surg. 2018;68:256–284. 12. Venermo M, Sprynger M, Desormais I, et al. Editor's choice - follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2019;58:641–653. 13. Hicks CW, Canner JK, Lum YW, et al. Long-term outcomes of an endovascular-first approach for diabetic patients with predominantly tibial disease treated in a multidisciplinary setting. Ann Vasc Surg. 2019;60:315–326.e2. 14. Dhand S. Multidisciplinary approach to PAD: who’s on your team? Semin Intervent Radiol. 2018;35:378–383. 15. Sloan FA, Feinglos MN, Grossman DS. Receipt of care and reduction of lower extremity amputations in a nationally representative sample of US Elderly. Health Serv Res. 2010;45:1740–1762. 16. Botros M, Kuhnke J, Embil JM, et al. Best practice recommendations for the prevention and management of diabetic foot ulcers. Foundations of Best Practice for Skin and Wound Management. 2017;1–68. 17. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recur- rence. N Engl J Med. 2017;376:2367–2375. Downloaded from http://ahajournals.org by on October 7, 2026